A5088683354- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Estrogen and related hormone effects
- Metastasis and carcinoma case studies
- Radiopharmaceutical Chemistry and Applications
- RNA modifications and cancer
- Immunotherapy and Immune Responses
- COVID-19 and healthcare impacts
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- Synthesis and biological activity
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cytokine Signaling Pathways and Interactions
- Monoclonal and Polyclonal Antibodies Research
- Prostate Cancer Treatment and Research
- Cancer-related molecular mechanisms research
- Economic and Financial Impacts of Cancer
- Lung Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- COVID-19 Clinical Research Studies
Ospedale San Luigi Gonzaga
2019-2023
University of Turin
2019-2023
Ospedale San Pietro Fatebenefratelli
2023
To assess time trends in the inclusion of health-related quality life (QoL) among study endpoints and reporting QoL results publications, randomised phase III oncology trials published between 2017 2021 were compared with previous 5 years. All issues 2012 by 11 major journals handsearched for primary publications adult patients solid tumours. Trials 2017-2021 2012-2016 three endpoints: (1) proportion including out all eligible publications; (2) presenting those (3) data publications. 388 446...
The response to immune checkpoint inhibitors (ICI) often differs between genders in non-small cell lung cancer (NSCLC), but metanalyses results are controversial, and no clear mechanisms defined. We aim at clarifying the molecular circuitries explaining differential gender-related anti-PD-1/anti-PD-L1 agents NSCLC.We prospectively analyzed a cohort of patients with NSCLC treated ICI as first-line approach, we identified determining efficacy 29 lines both genders, recapitulating patients'...
KRAS mutations occur in approximately 30% of lung adenocarcinomas, mainly codon 12 (83% cases), p.G12C being the prevalent one (40%), followed by p.G12V and p.G12D (22 16%, respectively). Treatment options for advanced mutant non-small-cell cancer (KRAS-MT NSCLC) are limited to chemotherapy immune checkpoint inhibitors (CPIs). However, clinical trials exploring specific targeted agents expected change treatment landscape this disease. Here, we describe design scientific rationale randomized,...
Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte (NLR) are markers of systemic inflammation associated with poor outcome in several solid tumors. We retrospectively investigated the prognostic role PLR and, secondly, NLR mCRPC patients treated abiraterone acetate (AA) or Enzalutamide (E), both pre- postdocetaxel setting.Two hundred twenty-five AA E basal blood count were divided three groups according to (PLR1<128; PLR2 128-190; PLR>190) two (<3 vs. ≥3). Outcome measures...
Background: The world, and Italy on the front lines, has experienced a major medical emergency due to novel coronavirus outbreak. Cancer patients are one of potentially most vulnerable cohorts people, but data about their management still few. Patients methods: In this monocentric retrospective study we included all SARS-CoV-2 oncological accepted, between March 27th April 19th 2020, at Onco-COVID Unit San Luigi Gonzaga Hospital, few Italian oncological-COVID wards. Data were obtained from...
Testicular metastases from renal cell carcinoma (RCC) are extremely rare. Tyrosine kinase inhibitors (TKI) the cornerstone of systemic therapy for metastatic RCC. We report a case testicular metastasis in 72-year-old patient with RCC that developed 17 years after nephrectomy and response to TKI treatment, retrospective literature search on RCC, indirect evidence described efficacy chemotherapy target lesions.
<p>Dose-dependent effects of fulvestrant and letrozole. ERα highNCI-H1975 cells were grown 24 h in fresh medium (Ctrl) or containing 0.1, 1, 10 nM fluvestrant (Fulv, panel a), an inhibitor, letrozole (Letr, b), aromatase inhibitor. As read-out assays, the expression ERα-target gene CXCL12 was measured by RT-PCR triplicate (panel amount 17-β-estradiol ELISA (technical duplicate, b). The relative Ctrl considered 1. Data are means+SD (n=3, biological replicates). *p<0.05,...
<p>Outcome of non-small cell lung cancer patients in LUAD TCGA cohort. a. OS adenocarcinoma (LUAD) dataset The Cancer Genome Atlas (TCGA), stratified according to the gender. F: females; M: males. b-c. female and male patients, median expression value CD274/PD-L1 mRNA. d-e. ESR1/ERα f-g. co-expression phenotypes: CD274high/ESR1high, CD274high/ESR1low, CD274low/ESR1high, CD274low/ESR1low. P:0.005 for CD274high/ESR1high versus CD274low/ESR1low group. h. Expression ERα mRNA, plotted PD-L1...
<p>Immunohistochemical characterization of PD-L1 and ERα in non-small cell lung cancer samples. a. Representative immunohistochemical images one NSCLC patient classified as PD-L1low (tumor proportion score, TPS: 60%) PD-L1high (TPS: 90%), according to the internal scale used our prospective study (see Results section for details). Bar: 20 µm. b. phospho(Ser118)ERα from ERαlow (Histo-score, Hscore: 30 cytosolic ERα, 90 nuclear ERα) ERαhigh (Hscore: 270 240 study. One ER+ (score:3+) ER-...
<p>Disaggregated data of ERα, 17-β-estradiol and PD-L1 levels in non-small cell lung cancer cells. a-c. Expression ERα mRNA, measured by RT-PCR (technical triplicates) (panel a), 17-β-estradiol, ELISA b), expression surface c), flow cytometry 29 human NSCLC lines, divided female (F)- or male (M)-derived primary tumor (P) metastatic (MTS) localization-derived non-smoker (NSm) smoker (Sm) patients. *p<0.05, **p<0.01: F versus M, P MTS, NSm Sm (ANOVA).</p>
<p>Molecular circuitries linking ERα and PD-L1. ERα, activated by the binding of 17-β-estradiol phosphorylation on Ser118 via EGFR/Akt EGFR/ERK1/2 axes, upregulates PD-L1 predicts a better response to pembrolizumab. However, lowering synthesis with letrozole or activity fulvestrant sensitizes non-small cell lung cancer pembrolizumab, relieving PD-L1-dependent immune-suppression, allowing expansion anti-tumor infiltrating lymphocytes, such as CD8+T-cells, NK cells Vγ9Vδ2+T cells. We...
<p>Levels of progesterone, testosterone and respective receptors in non-small cell lung cancer cells a-b. Levels progesterone (panel a) b), measured by ELISA (technical triplicates), female (F)-derived NCI-H1385 NCI-H1975 cells, male (M)-derived A549 NCI-H1650 cells. Data are means+SD (n=3, biological replicates). °p<0.05: M-derived versus mean F-derived (ANOVA). c-d. Progesterone receptor (PR; panel c) androgen (AR; d) mRNA, RT-PCR triplicates). The relative expression each gene...